{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T16:42:13Z","timestamp":1689352933923},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T00:00:00Z","timestamp":1403740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0099530","type":"journal-article","created":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T20:52:36Z","timestamp":1403815956000},"page":"e99530","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Moving Away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE) - Agents That Concern Prescribers and Patients: A Feasibility Study and Call for a Trial"],"prefix":"10.1371","volume":"9","author":[{"given":"Amit C.","family":"Achhra","sequence":"first","affiliation":[]},{"given":"Mark A.","family":"Boyd","sequence":"additional","affiliation":[]},{"given":"Matthew G.","family":"Law","sequence":"additional","affiliation":[]},{"given":"Gail V.","family":"Matthews","sequence":"additional","affiliation":[]},{"given":"Anthony D.","family":"Kelleher","sequence":"additional","affiliation":[]},{"given":"David A.","family":"Cooper","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2014,6,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel","volume":"308","author":"MA Thompson","year":"2012","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/QAD.0b013e328347fa16","article-title":"Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons","volume":"25","author":"AI Choi","year":"2011","journal-title":"AIDS"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11904-010-0047-3","article-title":"Abacavir and cardiovascular risk: reviewing the evidence","volume":"7","author":"D Costagliola","year":"2010","journal-title":"Curr HIV\/AIDS Rep"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1468-1293.2009.00724.x","article-title":"Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients","volume":"10","author":"A Hill","year":"2009","journal-title":"HIV Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1310\/hct1304-189","article-title":"Renal toxicity associated with antiretroviral therapy","volume":"13","author":"L Calza","year":"2012","journal-title":"HIV Clin Trials"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1212\/WNL.0b013e31821670fb","article-title":"Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients","volume":"76","author":"N Ciccarelli","year":"2011","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1371\/journal.pmed.0010019","article-title":"Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1","volume":"1","author":"F van Leth","year":"2004","journal-title":"PLoS Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1742-6405-10-33","article-title":"Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature","volume":"10","author":"AC Achhra","year":"2013","journal-title":"AIDS Res Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/S0140-6736(13)61164-2","article-title":"Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Paton N, Kityo C, Hoppe A, Hakim J, van Oosterhout J, <etal>et al<\/etal>.. (2013) A pragmatic randomised controlled strategy trial of three second-line treatment options for use in public health rollout programme settings: the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Kuala Lumpur, Malaysia.","DOI":"10.1186\/ISRCTN57333945"},{"key":"ref11","unstructured":"Cahn P, The GARDEL Study Group. (2013) Dual therapy with Lopinavir\/Ritonavir (LPV\/r) and Lamivudine (3TC) is non-inferior to standard triple drug therapy in Na\u00efve HIV-1 infected subjects: 48-week results of the GARDEL Study. 14th European AIDS Conference Brussels, Belgium."},{"key":"ref12","unstructured":"Stanford University. HIV Drug Resistance Database. HIV Drug Resistance Database. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/hivdb.stanford.edu\/\" xlink:type=\"simple\">http:\/\/hivdb.stanford.edu\/<\/ext-link>. Accessed 25 June 2013."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1128\/JCM.00510-13","article-title":"Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study","volume":"51","author":"E Tu","year":"2013","journal-title":"J Clin Microbiol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1046\/j.1464-2662.2001.00094.x","article-title":"Rates of combination antiretroviral treatment change in Australia, 1997\u20132000","volume":"3","year":"2002","journal-title":"HIV Med"},{"key":"ref15","unstructured":"Margolis D, Brinson C, Eron J, Richmond G, LeBlanc R, <etal>et al<\/etal>.. (2014) 744 and Rilpivirine as Two-Drug Oral Maintenance Therapy: LAI116482 (LATTE) Week 48 Results [Abstract 91LB]. 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA."},{"key":"ref16","unstructured":"Cotte L, Durant J, Brochier C, <etal>et al<\/etal>. (2013) Safety and efficacy of a Maraviroc-Raltegravir combination following a 6 month induction phase with Maraviroc-Raltegravir-Tenofovir-Emtricitabine in na\u00efve HIV-1 infected patients with CCR5 Virus: interim analysis of the No Nuc No Boost study [Abstract WEPE511]. IAS 2013. Kaula Lumpur, Malaysia."},{"key":"ref17","unstructured":"Ward DJ, O\u2019Neil D.J (2013) Nucleoside-sparing antiretroviral regimens in clinical practice. [Abstract H-659]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver USA."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1310\/hct1303-119","article-title":"A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results","volume":"13","author":"MJ Kozal","year":"2012","journal-title":"HIV Clinical Trials"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/QAI.0b013e318252f97e","article-title":"A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults","volume":"60","author":"D Carey","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3851\/IMP1647","article-title":"Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients","volume":"15","author":"DV Cordery","year":"2010","journal-title":"Antivir Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1310\/hct1005-337","article-title":"Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population","volume":"10","author":"C Allavena","year":"2009","journal-title":"HIV Clin Trials"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/1545109709332471","article-title":"Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants","volume":"8","author":"S Gupta","year":"2009","journal-title":"J Int Assoc Physicians AIDS Care"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1086\/597119","article-title":"Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes","volume":"199","author":"TJ Wilkin","year":"2009","journal-title":"J Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/QAI.0b013e31827b51b5","article-title":"Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study","volume":"62","author":"A Mills","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/jac\/dkt007","article-title":"Safety and feasibility of treatment simplification to atazanavir\/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir\/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study)","volume":"68","author":"S Di Giambenedetto","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"ref26","unstructured":"Calin R, Valantin M, Simon A, Paris L, Tubiana R, <etal>et al<\/etal>.. (2013) Raltegravir\/etravirine dual therapy as a virologically safe treatment option in suppressed HIV-1-infected patients without previous NNRTI failure. 7th International AIDS Society Conference on HIV Pathogenesis Treatment and Prevention. Kuala Lumpur, Malaysia."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jac\/dkt406","article-title":"Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study","volume":"69","author":"P Monteiro","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"ref28","first-page":"358","article-title":"Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals. [Erratum appears in J Antimicrob Chemother. 2011 Sep; 66(9): 2194]","volume":"66","author":"A Imaz","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/QAI.0b013e31820a9ae4","article-title":"Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine","volume":"56","author":"S Nozza","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref30","unstructured":"Tashima K SL, Andrade A, <etal>et al<\/etal>. (2013) Omitting NRTI from ARV regimens is not inferior to adding NRTI in treatment-experienced HIV+ subjects failing a protease inhibitor regimen: the ACTG OPTIONS study [Abstract 153LB]. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, Georgia, USA."},{"key":"ref31","unstructured":"Bedimo R, Drechsler H, Turner D, Moore T, Ghormley J, <etal>et al<\/etal>.. (2011) RADAR study: Raltegravir combined with boosted Darunavir has similar safety and antiviral efficacy as tenofovir\/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Rome."},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1089\/aid.2011.0336","article-title":"A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir\/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study","volume":"28","author":"I Ofotokun","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/hiv.12029","article-title":"Pharmacokinetics of the combination raltegravir\/atazanavir in HIV-1-infected patients","volume":"14","author":"A Jansen","year":"2013","journal-title":"HIV Medicine"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1089\/aid.2012.0280","article-title":"Short communication: lamivudine plus a boosted-protease inhibitor as simplification strategy in HIV-infected patients: proof of concept","volume":"29","author":"JL Casado","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.2165\/11538020-000000000-00000","article-title":"Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results","volume":"70","author":"B Taiwo","year":"2010","journal-title":"Drugs"},{"key":"ref36","first-page":"382","article-title":"Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. [Erratum appears in J Acquir Immune Defic Syndr. 2011 Nov 1;58(3): e102]","volume":"52","author":"A Imaz","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref37","unstructured":"Raffi F, Babiker A, Richert L, Molina J, George E, <etal>et al<\/etal>.. (2014) First-Line Raltegravir (RAL) + Darunavir\/Ritonavir (DRV\/r) is Non-inferior to Tenofovir\/Emtricitabine (TDF\/FTC) + DRV\/r: The NEAT 001\/ANRS 143 Randomised Trial [Abstract 84LB]. 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA."},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Katlama C, Assoumou L, Valantin MA, Soulie C, Duvivier C, <etal>et al<\/etal>.. (2014) Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. J Antimicrob Chemother.","DOI":"10.1093\/jac\/dkt536"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2217\/fvl.10.89","article-title":"Atazanavir\/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults","volume":"6","author":"CJ Achenbach","year":"2011","journal-title":"Future Virol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1310\/hct1305-233","article-title":"ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir\/abacavir\/lamivudine","volume":"13","author":"KE Squires","year":"2012","journal-title":"HIV Clin Trials"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/QAD.0b013e32834bbaa9","article-title":"Efficacy of a nucleoside-sparing regimen of darunavir\/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)","volume":"25","author":"B Taiwo","year":"2011","journal-title":"AIDS"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e1001240","DOI":"10.1371\/journal.pmed.1001240","article-title":"The ethics of switch\/simplify in antiretroviral trials: non-inferior or just inferior?","volume":"9","author":"A Carr","year":"2012","journal-title":"PLoS Med"},{"key":"ref43","unstructured":"Orrell C, Felizarta F, Nell A, Kakuda T, Lavreys L, <etal>et al<\/etal>. (2013): Etravirine 200 mg twice daily combined with atazanavir\/ritonavir 300\/100 mg or 400\/100 mg once daily in treatment-experienced patients: primary 48-week efficacy and safety analysis of the TEACH trial IAS. Kaula Lumpur, Malaysia."},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1097\/QAD.0b013e32834c4c06","article-title":"Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results","volume":"25","author":"B Gazzard","year":"2011","journal-title":"AIDS"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0099530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T16:22:52Z","timestamp":1689351772000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0099530"}},"subtitle":[],"editor":[{"given":"D. W.","family":"Cameron","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2014,6,26]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,6,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0099530","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,26]]}}}